HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Irmgard Andresen Selected Research

icatibant

12/2021Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain.
1/2021Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
1/2019Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey.
1/2019Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: Icatibant Outcome Survey findings.
4/2018Icatibant Outcome Survey in Patients with Hereditary Angioedema: Experience in Israel Compared with Other Countries.
1/2018Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey.
1/2018Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study.
1/2017Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Irmgard Andresen Research Topics

Disease

7Hereditary Angioedemas
12/2021 - 01/2017
1Hereditary Angioedema Types I and II
01/2019
1Body Weight (Weight, Body)
01/2018
1Overweight
01/2018
1Peripheral Nervous System Diseases (PNS Diseases)
12/2010
1Primary Immunodeficiency Diseases
12/2010
1Ischemia
01/2004
1Stroke (Strokes)
01/2004
1Neuroblastoma
01/2004
1Hypoalphalipoproteinemias (Hypoalphalipoproteinemia)
06/2003

Drug/Important Bio-Agent (IBA)

8icatibantIBA
12/2021 - 01/2017
1Bradykinin B2 ReceptorIBA
12/2021
1BradykininIBA
01/2018
1Immunoglobulins (Immunoglobulin)IBA
12/2010
1Intravenous Immunoglobulins (IVIG)FDA Link
12/2010
12',7'-dichlorofluoresceinIBA
01/2004
1N-Methylaspartate (NMDA)IBA
01/2004
1Reactive Oxygen Species (Oxygen Radicals)IBA
01/2004
1HDL LipoproteinsIBA
01/2004
1Adenosine Triphosphate (ATP)IBA
06/2003